[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344081-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","homa-beta-independently-predicts-survival-in-patients-with-advanced-cancer-on-treatment-with-immune-checkpoint-inhibitors","HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors","","Immune checkpoint inhibitors (ICIs) improve cancer outcomes, yet ICI-induced diabetes is rare and life-threatening. The impact of ICIs on insulin synthesis and secretion in patients without pre-existing diabetes remains unclear. This study prospectively evaluated glucose metabolism markers and insulin secretory capacity in 87 advanced cancer patients receiving ICI therapy, linking baseline and post-treatment HOMA-beta to overall survival and progression-free survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/homa-beta-independently-predicts-survival-in-patients-with-advanced-cancer-on-treatment-with-immune-checkpoint-inhibitors/344081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/homa-beta-independently-predicts-survival-in-patients-with-advanced-cancer-on-treatment-with-immune-checkpoint-inhibitors/344081.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study designed to investigate?","Question",{"text":63,"@type":64},"The study assessed how ICIs influence insulin synthesis and secretion by evaluating insulin secretory capacity alongside glucose metabolism markers in advanced cancer patients without diabetes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were included, and how were they evaluated?",{"text":68,"@type":64},"Eighty-seven patients with advanced cancer were included, and HbA1c, HOMA-IR, HOMA-beta, and C-peptide were prospectively measured during ICI treatment to relate these markers to prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What did HOMA-beta show in relation to survival outcomes?",{"text":72,"@type":64},"Patients with higher baseline HOMA-beta had longer overall survival and progression-free survival, and multivariable analysis indicated that a HOMA-beta value above the reported threshold independently predicted longer overall survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344081,1790140947,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Original Research PUBLISHED 11 December 2024 DOI 10.3389/fendo.2024.1439705  \nOPEN ACCESS  \nEDITED BY  \nMichaela Luconi,  \nUniversity of Florence, Italy  \nREVIEWED BY  \nJoe Varghese,  \nChristian Medical College and Hospital, India Srinadh Choppara,  \nUniversity of Michigan, United States  \n*CORRESPONDENCE  \nMayu Watanabe  \n [watanabe.mayu.rp@mail.hosp.go.jp](watanabe.mayu.rp@mail.hosp.go.jp)[ ](watanabe.mayu.rp@mail.hosp.go.jp)Jun Eguchi  \n[jeguchi@cc.okayama-u.ac.jp](jeguchi@cc.okayama-u.ac.jp)  \nRECEIVED 28 May 2024  \nACCEPTED 25 November 2024  \nPUBLISHED 11 December 2024  \nCITATION  \nWatanabe M, Eguchi J, Takamoto A,  \nKanzaki H, Noda Y, Kagawa S and Wada J (2024) HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors. Front. Endocrinol. 15:1439705 .  \ndoi: 10.3389/fendo.2024.1439705  \nCOPYRIGHT  \n© 2024 Watanabe, Eguchi, Takamoto, Kanzaki, Noda, Kagawa and Wada. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors  \nMayu Watanabe 1,2*, Jun Eguchi 1*, Atsushi Takamoto 3, Hiromitsu Kanzaki 4, Yohei Noda 3, Syunsuke Kagawa 5,6 and Jun Wada 1  \n1 Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2 Department of Diabetology and Metabolism, NHO Okayama Medical Center, Okayama, Japan, 3 Department of Urology, Fukuyama City Hospital, Hiroshima, Japan, 4 Department of Internal Medicine, Tsuyama Chuo Hospital, Okayama, Japan, 5 Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 6Clinical Cancer Center, Okayama University Hospital, Okayama, Japan  \nBackground: Although immune checkpoint inhibitors (ICIs) are effective cancer drugs, ICI-induced diabetes is a rare but a life-threatening adverse event for patients. The deleterious action of ICI on pancreatic beta-cell function is a concern. However, the inﬂuence of ICI on insulin synthesis and secretion inpatients with cancer without diabetes remains unknown.  \nMethods: This study included 87 patients diagnosed with advanced cancer. Glucose metabolism markers (HbA1c, HOMA-IR) and indicators of insulin secretory capacity (HOMA-beta, C-peptide) were prospectively evaluated inpatients with ICI-treated cancers to determine their association with cancer prognosis.  \nResults: Patients with overall survival (OS) ≥ 7 months had substantially higher HOMA-beta levels at baseline (p=0.008) and 1 month after ICI administration (p=0 . 006) compared to those with OS \u003C7 months . The median OS was signiﬁcantly longer in patients with HOMA-beta ≥ 64. 24 (13 months, 95%CI: 5.849–20.151, 37 events) than in those with HOMA-beta \u003C 64.24 (5 months, 95% CI: 3 .280–6.720, 50 events) (p=0 . 013) . Further, the median progression-free survival (PFS) was signiﬁcantly longer in patients with HOMA-beta ≥ 66.43 (4 months, 95%CI: 3.073–4.927, 33 events) than in those with HOMA-beta \u003C 66.43 (2 months, 95%CI: 1 .410–2. 590, 54 events) (p=0 . 025) . Additionally, multivariable logistic regression analysis revealed that a HOMA-beta value ≥ 64.24 independently predicted longer OS in ICI-treated patients.  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \nConclusions: Pre-ICI HOMA-beta level is linked to longer OS in ICI-treated patients. This connection is signiﬁcant and shows that insulin secretory capacity m","cbCaicGMp8QMSIoV","https://ap.wps.com/l/cbCaicGMp8QMSIoV","pdf",1830803,"English","# Background\n## Methods\n## Results\n## Conclusions\n## Key Words\n# Introduction","[{\"question\":\"What was the study designed to investigate?\",\"answer\":\"The study assessed how ICIs influence insulin synthesis and secretion by evaluating insulin secretory capacity alongside glucose metabolism markers in advanced cancer patients without diabetes.\"},{\"question\":\"How many patients were included, and how were they evaluated?\",\"answer\":\"Eighty-seven patients with advanced cancer were included, and HbA1c, HOMA-IR, HOMA-beta, and C-peptide were prospectively measured during ICI treatment to relate these markers to prognosis.\"},{\"question\":\"What did HOMA-beta show in relation to survival outcomes?\",\"answer\":\"Patients with higher baseline HOMA-beta had longer overall survival and progression-free survival, and multivariable analysis indicated that a HOMA-beta value above the reported threshold independently predicted longer overall survival.\"}]","HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors | PDF",1790052971,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33dfc084e559731201b4489f7daf80c0.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8234fe00cad77c8420d92b05ee81a9a.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92f8403886d90d742973abcab0a3a53b.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d275d6576edd2295a8ad914746f3f02b.webp",980,1385]